Research Analysts’ Recent Ratings Updates for Halozyme Therapeutics (HALO)

Halozyme Therapeutics (NASDAQ: HALO) has recently received a number of price target changes and ratings updates:

• 2/24/2026 – Halozyme Therapeutics was downgraded by Weiss Ratings from “buy (b-)” to “hold (c)”.
• 2/21/2026 – Halozyme Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “hold”.
• 2/19/2026 – Halozyme Therapeutics had its price target raised by Benchmark Co. from $75.00 to $90.00. They now have a “buy” rating on the stock.
• 2/19/2026 – Halozyme Therapeutics had its price target raised by Wells Fargo & Company from $65.00 to $75.00. They now have an “equal weight” rating on the stock.
• 2/18/2026 – Halozyme Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 2/10/2026 – Halozyme Therapeutics was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 2/3/2026 – Halozyme Therapeutics had its “buy” rating reaffirmed by Benchmark Co..
• 1/31/2026 – Halozyme Therapeutics was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 1/29/2026 – Halozyme Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 1/26/2026 – Halozyme Therapeutics was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 1/8/2026 – Halozyme Therapeutics had its price target raised by TD Cowen from $79.00 to $90.00. They now have a “buy” rating on the stock.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the sale, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 32,000 shares of company stock valued at $2,449,300 over the last three months. 2.90% of the stock is owned by corporate insiders.

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.